Related Experiment Videos
Decrease of erythropoietin level by human recombinant tumour necrosis factor alpha (hrec TNFalpha) in patients with
R Braczkowski1, W Romanawsky, A Danikiewicz
15th Department of Internal Medicine, The Silesian Medical University, Bytom, Poland. basiazub@poczta.onet.pl
Journal of Biological Regulators and Homeostatic Agents
|February 28, 2002
Summary
Patients with solid cancer and mild anemia have low erythropoietin (EPO) levels. Tumor necrosis factor-alpha (TNFα) therapy further suppresses EPO production, worsening anemia.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Anemia is a common complication in cancer patients, often linked to chronic inflammation and inappropriate erythropoietin (EPO) production.
- The exact mechanisms of Tumor Necrosis Factor-alpha (TNFα)-induced anemia and its impact on hematopoiesis require further clarification.
- Patients with advanced solid tumors often present with mild anemia, necessitating investigation into underlying causes like EPO dysregulation.
Purpose of the Study:
- To investigate the influence of recombinant human TNFα (hrec TNFα) administration on plasma EPO concentration in patients with advanced solid tumors.
- To assess the effect of hrec TNFα on the degree of anemia in palliative care cancer patients.
- To compare EPO levels in anemic cancer patients with those in anemic non-cancer patients.
Main Methods:
- A clinical study involving patients with advanced solid tumors and mild anemia (hematocrit [HT] 36.1 +/- 1.0%).
- Administration of hrec TNFα at doses of 75 μg/day (cycle I) and 150 μg/day (cycle II) with plasma EPO measurements before and after each cycle.
- A control group of anemic non-cancer patients (HT 36 +/- 1.1%) for comparison of baseline EPO levels.
Main Results:
- Anemic cancer patients exhibited significantly lower baseline plasma EPO levels (17.1 +/- 2.5 mU/ml and 14.6 +/- 3.8 mU/ml) compared to anemic non-cancer controls (54.2 +/- 8 mU/ml).
- TNFα administration led to a significant decline in plasma EPO levels in cancer patients after both cycle I (17.1 +/- 2.5 to 9.0 +/- 1.5 mU/ml) and cycle II (14.6 +/- 3.8 to 8.4 +/- 2.0 mU/ml).
- The study suggests that cancer patients with mild anemia have inappropriately low EPO concentrations.
Conclusions:
- Patients with solid cancer and mild anemia are characterized by inappropriately low plasma EPO concentrations.
- Therapy with TNFα exerts a suppressive effect on EPO secretion in these cancer patients.
- These findings highlight a potential mechanism contributing to anemia of chronic disease in cancer.